Pathophysiology and management of hypoglycemia in diabetes

Ann N Y Acad Sci. 2022 Dec;1518(1):25-46. doi: 10.1111/nyas.14904. Epub 2022 Oct 6.

Abstract

In the century since the discovery of insulin, diabetes has changed from an early death sentence to a manageable chronic disease. This change in longevity and duration of diabetes coupled with significant advances in therapeutic options for patients has fundamentally changed the landscape of diabetes management, particularly in patients with type 1 diabetes mellitus. However, hypoglycemia remains a major barrier to achieving optimal glycemic control. Current understanding of the mechanisms of hypoglycemia has expanded to include not only counter-regulatory hormonal responses but also direct changes in brain glucose, fuel sensing, and utilization, as well as changes in neural networks that modulate behavior, mood, and cognition. Different strategies to prevent and treat hypoglycemia have been developed, including educational strategies, new insulin formulations, delivery devices, novel technologies, and pharmacologic targets. This review article will discuss current literature contributing to our understanding of the myriad of factors that lead to the development of clinically meaningful hypoglycemia and review established and novel therapies for the prevention and treatment of hypoglycemia.

Keywords: counter-regulatory hormones; hypoglycemia; hypoglycemia-associated autonomic failure; impaired awareness.

Publication types

  • Review

MeSH terms

  • Blood Glucose
  • Diabetes Mellitus, Type 1* / therapy
  • Glucose
  • Humans
  • Hypoglycemia* / etiology
  • Hypoglycemia* / therapy
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use

Substances

  • Insulin
  • Glucose
  • Blood Glucose
  • Hypoglycemic Agents